ProPhase Labs, Inc. Stock

$0.34

0.00%

Nasdaq, Aug 30, 12:50 am CET

ISIN

US74345W1080

Symbol

PRPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

ProPhase Labs, Inc. Stock price

$0.34

-2.07 85.99% 5Y

Nasdaq, Closing price Fri, Aug 29 2025

-0.01 2.42%

ISIN

US74345W1080

Symbol

PRPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$14.1m

Enterprise Value

$21.6m

Net debt

$7.6m

Cash

$170.0k

Shares outstanding

41.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.4 | 0.6

EV/Sales

3.7 | 1.0

EV/FCF

negative

P/B

1.2

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | -22.8%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$5.8m | $21.8m

EBITDA

$-9.3m | $19.3m

EBIT

$-15.5m | $-10.5m

Net Income

$-7.1m | $-23.7m

Free Cash Flow

$-11.2m

Growth (TTM | estimate)

Revenue

-67.6% | 221.8%

EBITDA

65.2% | 160.4%

EBIT

54.4% | 72.8%

Net Income

73.1% | 55.5%

Free Cash Flow

37.1%

Financial Health

Equity Ratio

11.6%

Return on Equity

-725.7%

ROCE

-94.4%

ROIC

-63.4%

Debt/Equity

0.7

EPS

$-0.2

FCF per Share

$-0.3

Short interest

6.8%

Employees

Rev per Employee

$70.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

ProPhase Labs, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a ProPhase Labs, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a ProPhase Labs, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from ProPhase Labs, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	5.82 5.82	68% 68% 100%
- Direct Costs	4.73 4.73	76% 76% 81%
Gross Profit	1.10 1.10	167% 167% 19%
- Selling and Administrative Expenses	16 16	47% 47% 281%
- Research and Development Expense	0.22 0.22	80% 80% 4%
EBITDA	-9.33 -9.33	65% 65% -160%
- Depreciation and Amortization	6.16 6.16	14% 14% 106%
EBIT (Operating Income) EBIT	-15 -15	54% 54% -266%
Net Profit	-7.09 -7.09	73% 73% -122%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ProPhase Labs, Inc. Stock News

Neutral

Seeking Alpha

●

13 days ago

ProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call Transcript

ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2025 Earnings Conference Call August 13, 2025 2:00 PM ET Company Participants Ted William Karkus - Chairman & CEO Operator Welcome to today's presentation. My name is Noella Alexander-Young, virtual event moderator here at Renmark Financial Communications.

Neutral

GlobeNewsWire

●

13 days ago

ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders

UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement (“DEF 14A”) with the U.S. Securities and Exchange Commission (“SEC”) on Friday, August 15, 2025 and received a “no further comments” letter from the SEC's D...

Neutral

GlobeNewsWire

●

19 days ago

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart ™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE ...

More ProPhase Labs, Inc. News

Company Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. Its products include TK supplement. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Doylestown, PA.

Head office	United States
CEO	Ted Karkus
Employees	96
Founded	1989
Website	www.prophaselabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now